Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Sponsor: NRG Oncology
Listed as NCT00365105, this PHASE3 trial focuses on Breast Cancer and Lung Cancer and remains completed. Sponsored by NRG Oncology, it has been updated 11 times since 2006, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Oct 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jul 2019 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
May 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Jul 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NRG Oncology
- National Cancer Institute (NCI)
- Radiation Therapy Oncology Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Abington, United States, Akron, United States, Albuquerque, United States, Alexandria, United States, Alliance, United States, Ames, United States, Ann Arbor, United States, Appleton, United States, Arlington Heights, United States, Asheville, United States and 107 more location s